Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

HDAC Inhibitor MGCD0103 Demonstrates substantial Response Rate in Two Clinical Trials

Clinical Data Presented on Pilot Pharmacokinetic Study of Oral Azacitidine

Exelixis Reports Comprehensive XL880 Phase I Data At ASCO

Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

Studies Investigating Vidaza in Alternate Dosing Schedules in MDS and in Combination with Valproic Acid for Solid Tumors Presented at the American Society of Clinical Oncology 43rd Annual Meeting

* In alternate dose trial, transfusion independence achieved for 65% to 80% of patients transfusion dependent at baseline

CHICAGO, Ill., June 2, 2007 - Pharmion Corporation (NASDAQ: PHRM) reported today the interim results of several Vidaza (azacitidine for injection) studies in the treatment of hematologic malignancies and advanced solid tumors. These data were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. (June 1-5, 2007). Pharmion's epigenetic anti-cancer products, which include Vidaza, MCGD0103 and oral Azacitidine, are being investigated in the treatment of hematologic malignancies and solid tumors and are the subject of poster and oral presentations at the Meeting.

"As we continue to evaluate alternative dosing and schedules for Vidaza in MDS, and its potential in solid tumors, we are increasingly impressed with the activity this drug has in multiple tumor types," said Patrick J. Mahaffy, president and CEO of Pharmion. "These studies will help provide us with insight not only into the continuing development of parenteral Vidaza, but, in particular, provide us direction for the development of oral azacitidine."

Tolerability and hematologic improvement assessed using three alternative dosing schedules of azacitidine
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:3/2/2015)... 2, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) ... year ended December 31, 2014 on March 9, 2015. The Company ... on Thursday, March 12, 2015, at 5:00 pm ET. The call ...   , , , LIVE CALL:  ... code 92238648. , , , , ...
(Date:3/1/2015)... Telbec/ -   Ergoresearch Ltd (TSXV: ERG) – based ... the « Équilibre, orthèses et biomécanique» banner  – ... December 31, 2014. All dollar amounts in the present ... for the second quarter of fiscal year 2015 ended ... 8,8 % compared to revenues of $ 4 489 330 ...
(Date:3/1/2015)... 2015  USPlabs has notified the Food and ... that media reports saying that a company product ... February 28, 2015, the Center for Drug Evaluation ... the contamination of a dietary supplement product labeled ... as "OEP") with a prescription drug active ingredient, ...
Breaking Medicine Technology:ImmunoCellular Therapeutics to Report 2014 Financial Results on March 9, 2015; a Business Update Conference Call and Webcast is Scheduled for March 12, 2015 2Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 2Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 3Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 4OEP Product Is Counterfeit 2
(Date:3/1/2015)... 02, 2015 Security Life Insurance ... benefits market, announced the addition of stand-alone individual ... Vision Insurance launched today, complete with two plan ... utilize the VSP® Vision Care network encompassing a ... practice space. The PrimeStar Select Vision plan will ...
(Date:3/1/2015)... 2015 Women’s Excellence now offers ... (OAB) symptoms, such as a strong need to urinate with ... medication (anticholinergic) does not work well enough or cannot be ... another approach to targeting the source of OAB, the bladder ... and bladder muscle, blocking the signals that trigger OAB. ...
(Date:3/1/2015)... March 01, 2015 Researchers say working ... so many sheet metal workers contract malignant mesothelioma. Surviving ... report on its website. Click here to read ... Construction Research and Training monitored 17,345 sheet metal workers ... number of them died of mesothelioma or another ...
(Date:3/1/2015)... New York, NY (PRWEB) March 01, 2015 ... ) has grown substantially over the past few weeks ... Liebhard LLP are actively filing claims, the Firm announces. ... 2015 reflects 7,713 cases in the Bergen County proceeding ... Ethicon Inc., compared with a few weeks earlier, when ...
(Date:3/1/2015)... 2015 “ The Barrel Mill ” was ... which takes a look at the latest and coolest technology ... of NewsWatch and a technology expert, conducted the review and ... to drinks. , According to Home Distillation of Alcohol, it's ... Well, there’s a pretty cool product that’ll help anyone achieve ...
Breaking Medicine News(10 mins):Health News:Security Life Insurance Company Launches Individual Vision Insurance Product 2Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2
... ... PhD, JD, is Keynote Speaker on the Failed War on Drugs , ... Las Vegas, NV (PRWEB) September 11, 2009 -- ... Drug Policy Alliance advocating for drug reform in the United States as keynote speaker former ...
... acoustic neuromas , FRIDAY, Sept. 11 (HealthDay News) -- Last ... or the sound of a dog barking. She was 22. ... type 2 (NF2), a condition characterized by tumors in the ... cranial nerve in one ear. , The result: increasing hearing ...
... affects insulin resistance, study finds, , FRIDAY, Sept. 11 (HealthDay ... insight into type 2 diabetes, potentially leading to better treatment ... appears to be linked to diabetes, affects how the body ... published Sept. 6 in Nature Genetics . , "Most ...
... Duane Reade Holdings Inc., the largest drug store in metropolitan New ... 2009 Komen New York City Race For The Cure, the Company, ... raised $330,000 to increase awareness of breast cancer and to assist ... year that Duane Reade has proudly sponsored this momentous event, with ...
... , , MADISON, N.J. and ... (FDA) today cleared the OVA1(TM) Test, the first blood test that, ... at risk for a malignant pelvic mass. OVA1 is the first ... with high sensitivity prior to biopsy or exploratory surgery, even if ...
... , , , ... Gardasil, declined by a third this year, and three years after ... women remain unvaccinated -- despite millions spent on advertising and lobbying ... , , Michelle Steward, assistant professor of marketing ...
Cached Medicine News:Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 2Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 3Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 2Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 3Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 3Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 2Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 3Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 4Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 5Health News:HPV Vaccine Study Shows Why Few Women Getting Shots 2
... Graft, the newest vascular graft offering from ... in vascular surgical products for more than ... kinking and compression problems that can ... provides all of the benefits of a ...
... The drilling and rasping necessary in cruciate ... roughness on the bone surface. This condition, ... can damage the cruciate replacement. The GORE ... cruciate ligament reconstruction procedures. The tool functions ...
Vikingselect™ Intra-Operative Monitoring (IOM)....
... has been designed by practicing neurophysiologists ... the ever changing and demanding medical ... data from multiple modalities, including: SSEPs ... multiple patients at multiple sites. Our ...
Medicine Products: